uniQure NV (FRA:UQ1) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UQ1 uniQure NV FRA:UQ1
53 GF Score
Price €35.85
GF Value €5.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:UQ1
53GF Score
uniQure NV FRA:UQ1
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is uniQure NV (FRA:UQ1) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of €35.85 is trading 550.6% above its estimated GF Value™ of €5.51. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for FRA:UQ1:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €5.51 vs. price of €35.85 (550.6% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the FRA:UQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
53GF Score

Get the complete analysis for FRA:UQ1

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.85
Price
€5.51
GF Value